25 December 2024

Gilbert H. Kleiman, Director at Glacos Company (NYSE:), recently sold 10,000 shares of the company's common stock. The company, which has a market cap of $8.2 billion, has seen its shares rise nearly 87% year-to-date. The sale, which occurred on December 20, 2024, was part of a prearranged Rule 10b5-1 trading plan, approved in June 2024. The shares were sold at a weighted average price of $150.28, for a total of approximately $1.5 million. according to InvestingProThe stock is trading near its 52-week high of $151.92, indicating strong momentum.

In a related transaction, Kleiman also exercised stock options to acquire 10,000 shares at $32 per share. Following these transactions, Kleiman directly owns 32,336 shares, including 2,611 restricted stock units that have not yet vested. The transactions were filed with the Securities and Exchange Commission on December 23, 2024. InvestingPro Subscribers can access 12 additional key insights into Glaukos Corp.'s financial health and market performance through Pro Research's comprehensive report.

In other recent news, Glaukos Corporation has submitted a New Drug Application to the FDA for Epioxa, a non-surgical treatment for keratoconus. If approved, Epioxa will be the first non-surgical corneal cross-linking treatment approved by the US Food and Drug Administration. In financial developments, Glaukos received approximately $53.2 million from unwinding a portion of capped call transactions related to its 2.75% convertible senior notes due 2027.

Analyst firms have provided various forecasts for Glaukos. Citi upgraded Glaukos from Neutral to Buy, anticipating a positive turn in sales of its iDose product in 2025. UBS initiated coverage of Glaukos with a Buy rating, attributing the company's high 20% compound annual growth rate to iDose's success. Mizuho (NYSE:) Securities, however, maintained a Neutral rating on Glaukos stock but increased its price target in anticipation of an important year ahead for the company.

In related news, Procept BioRobotics launched a public offering of common stock valued at $175 million and achieved strong revenue growth of 66% in the third quarter. Morgan Stanley (NYSE:) Procept BioRobotics has initiated coverage with an Overweight rating, suggesting a path to further upside. Truist Securities maintained a Buy rating on Procept BioRobotics, raising its price target following the company's strong third-quarter performance.

This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.

Leave a Reply

Your email address will not be published. Required fields are marked *